Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory

functions and clearance of apoptotic cells

Ana C. G. Salina[1†], Douglas dos-Santos[1†], Tamara S. Rodrigues[1†], Marlon Fortes-Rocha[1], Edismauro G. Freitas-Filho[1], Daniel L. Alzamora-Terrel[1], Mikhael H. F. de Lima[2], Daniele C. Nascimento[2], Ícaro M. S. Castro[3], Camila M. Silva[2], Juliana E. Toller-Kawahisa[2], Amanda Becerra[1], Samuel Oliveira[1], Diego B. Caetité[2], Leticia Almeida[1,4], Adriene Y. Ishimoto[1], Thais M. Lima[1], Ronaldo B. Martins[1], Flavio Veras[2], Natália B. do Amaral[5], Marcela C. Giannini[5], Letícia P. Bonjorno[5], Maria I. F. Lopes[5], Maira N. Benatti[7], Sabrina S. Batah[7], Rodrigo C. Santana[5], Fernando C. Vilar[5], Maria A. Martins[6], Rodrigo L. Assad[5], Sergio C. L. de Almeida[5], Fabiola R. de Oliveira[5], Eurico Arruda Neto[1], Thiago M. Cunha[2,4], José C. Alves-Filho[2,4], Fernando Q. Cunha[2,4], Alexandre T. Fabro[7], Helder I. Nakaya[3,4], Dario S. Zamboni[1,4], Paulo Louzada-Junior[5], Rene D. R. Oliveira[5], Larissa D. Cunha[1]*

[1]Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
[2]Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
[3]Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Brazil.
[4]Center of Research in Inflammatory Diseases (CRID), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
[5]Divisão de Imunologia Clinica, Emergência, Doenças Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
[6]Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
[7]Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

[†] A.C.G.S., D.S., and T.S.R. equally contributed to this work.

* Correspondence: Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos
                         Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
                         Av. Bandeirantes 3900, Ribeirão Preto, SP 14049-900, Brazil
                         Tel: +55 16 33153319
                         larissacunha@usp.br
                         (ORCID iD: 0000-0002-1290-0263),

Abstract

COVID-19 is a disease of dysfunctional immune responses, but the mechanisms triggering

immunopathogenesis are not established. The functional plasticity of macrophages allows this

cell type to promote pathogen elimination and inflammation or suppress inflammation and

promote tissue remodeling and injury repair. During an infection, the clearance of dead and

dying cells, a process named efferocytosis, can modulate the interplay between these contrasting

functions. Here, we show that engulfment of SARS-CoV2-infected apoptotic cells (AC)

exacerbates inflammatory cytokine production, inhibits the expression of efferocytic receptors,

and impairs continual efferocytosis by macrophages. We also provide evidence supporting that

monocytes and macrophages from severe COVID-19 patients have compromised efferocytic

capacity. Our findings reveal that dysfunctional efferocytosis of SARS-CoV-2-infected cell

corpses suppress macrophage anti-inflammation and efficient tissue repair programs and provide

mechanistic insights for the excessive production of pro-inflammatory cytokines and

accumulation of tissue damage associated with COVID-19 immunopathogenesis.

KEYWORDS: COVID-19, macrophage, macrophage polarization, efferocytosis,

hyperinflammation, tissue repair

Introduction

Because of its recent emergence, the pathogenesis of COVID-19 is still poorly defined. Patients with severe disease can progress to pneumonia, development of acute respiratory distress syndrome (ARDS) and respiratory failure, septic shock, and multiorgan dysfunction (Siddiqi and Mehra, 2020). These clinical manifestations of the disease have been associated with a dysregulated host immune response and compromised function of the myeloid compartment, suggesting that hyperinflammation and unresolved tissue damage could both contribute to the pathogenesis of severe COVID-19 (Blanco-Melo et al., 2020; Lucas et al., 2020; Rodrigues et al., 2020; Schulte-Schrepping et al., 2020; Silvin et al., 2020; Valle et al., 2020; Veras et al., 2020).

Macrophages and monocytes promote disease tolerance and resolution of inflammation by sensing pathogen and host-derived pathogenic signals and programming their gene expression toward an anti-inflammatory, pro-resolution, and wound-healing phenotype (Martins et al., 2019). This host-protective programming reduces inflammatory cytokine production by other immune and non-immune cells and promotes the repair of damaged tissue to sustain physiological function and re-establish homeostasis (Murray and Wynn, 2011). During the repair process, the efficient clearance of dying cells prevents further tissue dysfunction caused by uncontrolled cytotoxicity and the release of damage-associated molecular patterns (DAMP). Defects in sensing, ingesting, and degradation of dead and dying cells through efferocytosis cause chronic inflammation and autoimmune diseases (Boada-Romero et al., 2020). In addition to preventing the deleterious effects of secondary necrosis, efferocytosis also couples corpse

internalization to other environmental cues (such as local cytokines and metabolites) to

temporally and spatially regulate macrophage anti-inflammatory and tissue repair functions (A-

Gonzalez et al., 2017; Bosurgi et al., 2017; Perry et al., 2019). While the clearance of apoptotic

cells is often associated with alternative macrophage programming, the identity of the dying cell,

the type of cell death, and the context of death (either sterile or infectious) can modulate the

nature of the macrophage response (Rothlin et al., 2020).

While infection with SARS-CoV2 induces the recruitment of immune cells to the lungs, their

role in host defense and the causes for the dysfunction during disease progression remain elusive.

Here, we sought to determine how macrophages operate when responding to dying epithelial

cells infected with SARS-CoV-2. We found that the presence of viable SARS-CoV-2 in cell

corpses dysregulates macrophage anti-inflammatory responses to the efferocytosis of apoptotic

cells, promoting excessive production of inflammatory IL-6 and IL-1β while disrupting the

efficient continual clearance of dead cells required for effective tissue repair. We also provide

evidence that the expression of efferocytic genes is reduced in macrophages from severe

COVID-19 patients and that monocytes from hyperinflammatory patients are also less efficient

in the clearance of apoptotic cells. Therefore, SARS-CoV-2 infection and the clearance of

infected dying cells disrupt macrophage host-protective functions associated with

immunopathological manifestations of COVID-19.

Results

Macrophages engulf dying cells carrying viable SARS-CoV-2

SARS-CoV-2 infection causes cytopathic effects in human and primate epithelial cells (Chu et

al., 2020; Zhu et al., 2020), possibly mediated by activation of multiple cell death pathways

(Chan et al., 2020; Shaohua Li et al., 2020; Shufen Li et al., 2020; Mulay et al., 2021; Ren et al.,

2020; Zhu et al., 2020) . Notably, inhibition of apoptosis ameliorates cytokine expression and

tissue damage in the lungs of SARS-CoV-2-infected mice, indicating that apoptosis in the lungs

is pathogenic (Chu et al., 2021). Immunofluorescent labeling of active caspase-3 in lung tissues

of deceased COVID-19 patients confirmed the induction of apoptosis in pseudostratified

epithelia, type I and II pneumocytes infected with replicant SARS-CoV2 (**Fig. 1A**, and **Fig.**

S1A). Examination of lung tissues also revealed evidence of macrophages with internalized

epithelial cells and SARS-CoV-2, suggesting the uptake of infected epithelial cells by

macrophages (**Fig. 1B**). Consistent with previous reports (Chu et al., 2020; Ren et al., 2020; Zhu

et al., 2020), infection with SARS-CoV-2 induced apoptosis in immortalized epithelial cell lines

(both human lung epithelial Calu-3 and simian kidney epithelial Vero CCL81 cells), as shown by

annexin V staining (**Fig 1C** and **Fig. S1B**) and caspase-3 activation (**Fig. 1D**). We performed the

Median Tissue Culture Infection Dose (TCID50) assay and found that viral particles obtained

from isolated apoptotic Vero and Calu-3 cells induced cytopathic effect to an equivalent extent

as those released in the culture supernatants (**Fig. S1C**). Furthermore, we isolated annexin V-

labelled apoptotic cells (AC) from SARS-CoV-2-infected cell culture and confirmed that they

carry viable viral particles (**Fig. 1E**). Therefore, viable SARS-CoV-2 is retained within infected,

apoptotic epithelial cells.

Exposure of phosphatidylserine (PtdSer) on the outer plasma membrane of cells undergoing

regulated cell death (RCD), as observed by annexin V binding to infected dying cells (**Fig. 1B**),

is the most ubiquitous signal that triggers their phagocytosis (Fadok et al., 1992; Nagata, 2018).

To determine whether phagocytes efficiently engulf SARS-CoV-2-infected apoptotic cells

(Cov2-AC), we used flow cytometry to assess their uptake by primary human macrophages and

macrophages differentiated from THP-1 monocytes. We observed that macrophages efficiently

engulf CoV2-AC, similarly to the uptake of sterile, UV-irradiated apoptotic cells (UV-AC) (**Fig.**

1F and Fig. 1SD). Analysis by confocal microscopy and staining for Spike protein confirmed

the presence of SARS-CoV-2 in engulfed cell corpses (**Fig. 1G**). Finally, either stimulation with

infected or sterile dying cells did not robustly affect macrophages viability up to 24 h post-

treatment (**Fig. S1E**).

These results demonstrate that macrophages engulf cell corpses carrying viable particles of

SARS-CoV-2, offering a framework to investigate their effects on macrophage function.

Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory

function

We next addressed the effect of the engulfment of SARS-CoV-2-infected apoptotic cells in

macrophages. The uptake of sterile apoptotic cells often promotes macrophage functional

polarization toward an anti-inflammatory and tissue repair phenotype (Doran et al., 2020). We

first observed that stimulation of primary monocyte-derived macrophages with CoV-2-AC, but

not infection with SARS-CoV-2, consistently reduced the expression of genes associated with

alternative programming to tissue remodeling and secretion of immune-modulatory mediators

such as *CCL18*, *CD206* (also known as *MRC1*), *MMP9*, *PPARγ* and *CD163* (**Fig. 2A**).

Furthermore, stimulation with UV-irradiated apoptotic Vero cells (UV-AC) increased both gene

(**Fig. 2A**) and protein (**Fig. 2B, Fig. S2A**) expression of the anti-inflammatory marker CD206.

However, upregulation of MRC1 at the gene or protein levels did not occur in response to

stimulation with CoV2-AC (**Fig. 2A and B**). We obtained similar results in THP1-derived

macrophages stimulated with CoV2-AC obtained from either Calu-3 or Vero cells infected with

SARS-CoV-2 (**Fig. S2B-D**). Stimulation with the conditioned supernatants of infected dying

cells (containing putative DAMP, cytokines produced by epithelial cells, extracellular vesicles,

and released virions) or direct infection with SARS-CoV-2 did not induce *MRC1* transcription

(**Fig. 2A, Fig. S2B**) or translation (**Fig. 2B, Fig. S2C** and **D**) in macrophages. To determine if

viral viability was required to modulate CD206 expression by infected apoptotic cells, isolated

CoV2-AC were exposed to UV irradiation for virus inactivation (**Fig. S2E**). Notably,

macrophages treated with epithelial AC containing inactivated SARS-CoV-2 exhibited increased

CD206 surface expression, similar to that of UV-AC (**Fig. 2C**). This finding suggests that viable

SARS-CoV-2 actively represses alternative programming carried in dying cells and is not

primarily enforced by the type of cell death caused by the infection. Efferocytosis of sterile UV-

AC in the presence of SARS-CoV-2 still induced higher expression of CD206 in macrophages

(**Fig. 2D**). Therefore, the suppression of the CD206 response required delivery of viral particles

within cell corpses to macrophages.

Conversely, the uptake of CoV2-AC, but not UV-AC, significantly increased *IL6* expression in

monocyte- and THP-1-derived macrophages (**Fig. 2E** and **Fig. S2F**, respectively). The uptake of

CoV2-AC also induced robust secretion of inflammatory IL-6 and IL-1β, in both primary (**Fig.**

2F) and THP-1-derived macrophages (**Fig. S2G** and **H**). Importantly, we did not detect these

cytokines in macrophages stimulated with the cell-free conditioned supernatants, and therefore

this effect was not due to immune mediators or viral particles released from infected epithelial

cells (**Fig. 2F** and **Fig. S2F-H**). Further, the induction of inflammatory cytokines by SARS-CoV-

2-loaded corpses required the presence of viable viral particles, as UV-treatment or

paraformaldehyde-fixation of isolated CoV2-AC abrogated IL-6 secretion (**Fig. 2G**). Notably,

we did not observe robust production of IL-6 in response to dying epithelial cells infected with

Coxsackievirus (**Fig. S2I** and **Fig. 2H**). This result suggests that augmented pro-inflammatory

cytokine production is not a universal response of macrophages to the uptake of cell corpses

infected with positive single-strand viruses.

To confirm the requirement of recognition and binding of CoV2-AC to promote inflammatory

skewing, we stimulated macrophages in the presence of annexin V to mask PtdSer exposed on

the surface of the apoptotic cells. In the absence of PtdSer ligation, macrophages did not produce

IL-6 in response to CoV2-AC (**Fig. 2I** and **Fig. S2J**). Stimulation of macrophages in the

presence of actin depolymerization inducer Cytochalasin D, which allows corpse binding but no

internalization, also attenuated IL-6 production (**Fig. 2J**).

Collectively, these findings support that sensing and engulfment of dying cells carrying viable

SARS-CoV-2 switch the anti-inflammatory, resolutive programming in response to efferocytosis

toward an inflammatory phenotype. The exacerbated cytokine production observed in response

to the efferocytosis of infected cell corpses by macrophages may contribute to the cytokine storm

associated with COVID-19 hyperinflammatory syndrome.

Efferocytosis of SARS-CoV-2-infected dying cells suppresses continual clearance of

apoptotic cells

Several receptors mediate efferocytosis through recognition of PtdSer on the surface of a dying

cell, either by direct binding or through a bridging molecule (Boada-Romero et al., 2020;

Penberthy and Ravichandran, 2016). We found that engulfment of CoV2-AC by primary

macrophages reduced the transcription of such PtdSer receptors, including the scavenger

receptors *CD36* and *SRA-I*, α*Vβ5* integrin (*ITGB5*), and T cell immunoglobulin mucin receptor 4

(*TIM4*) and MER proto-oncogene tyrosine kinase (*MERTK*) (**Fig. 3A**). In THP-1-macrophages,

we also observed reduced expression of *SRA-I, ITGB5,* and *TIM4* receptors in response to

infection with SARS-CoV-2 (**Fig. S2K**). Phagocytes can ingest multiple corpses in subsequent

rounds of efferocytosis (Miyanishi et al., 2007; Morioka et al., 2018; Park et al., 2011; Yurdagul

et al., 2020). Previous *in vivo* work showed that macrophages must continually remove ACs to

promote efficient repair of injury and prevent the accumulation of secondarily necrotic cells

(Wang et al., 2017; Yurdagul et al., 2020). To determine if repression of efferocytic receptors

affects additional uptake of dying cells, we treated macrophages with CoV2-AC and

subsequently fed them with apoptotic human Jurkat cells (Jurkat-AC). We found that the

engulfment of SARS-CoV-2-infected corpses suppressed the efferocytosis of other apoptotic

cells (**Fig. 3B-D, Fig. S2L**). As infection with SARS-CoV-2 reduced the expression of some

efferocytic receptors in THP-1 macrophages (**Fig. S2K**), we also tested if it affected the uptake

of apoptotic cells. Comparatively, infection with SARS-CoV-2 reduced AC clearance to a lower

extent than prior uptake of CoV2-AC (**Fig. S2M**). Thus, efferocytosis of SARS-CoV-2-infected

dying cells affects the expression of efferocytic receptors and impairs the continual removal of

apoptotic cells by macrophages.

Lung monocytes and macrophages of severe COVID-19 patients express reduced levels of

efferocytic receptors

To gain insight into the contribution of dysfunctional efferocytosis in COVID-19 pathogenesis,

we assessed the expression of efferocytic receptors by immunofluorescence in lung tissues

obtained from autopsies of deceased COVID-19 patients. We found a reduction in the protein

levels of CD36 in S1009[+] infiltrating phagocytes in the lungs of COVID-19 patients compared to

control tissues (**Fig. 4A**). Phagocytes in the lungs of COVID-19 patients also expressed lower

protein levels of MERTK (**Fig. 4B**).

Using publicly available single-cell RNA sequencing (scRNA-seq) data from bronchoalveolar

lavage (BAL)(Liao et al., 2020), we performed enrichment analysis using the genes differentially

expressed (DEG) in mild and severe COVID-19 patients compared with healthy individuals. We

targeted efferocytosis-related gene ontology annotated pathways and customized gene sets based

on the literature (Boada-Romero et al., 2020; Penberthy and Ravichandran, 2016) (**Table S1**).

Clusters identified as macrophages (Liao et al., 2020) revealed significant repression of gene sets

related to efferocytosis in severe patients (**Fig. 4C**). While differences in the comparison

between moderate and severe patients were observed in clusters of early infiltrating phagocytes

(S1009$^+$ CCL18$^-$), they were more pronounced in mature, putative anti-inflammatory

macrophages (S11009$^-$ CCL18$^+$). Notably, reassessment on scRNAseq by Ren et al. (2021)

showed enrichment in pathways related to efferocytosis for genes repressed in alveolar

macrophages which were positive for SARS-CoV-2 RNA compared with those which were

negative to the virus (**Fig. 4D**). This finding is consistent with the notion that uptake of infected

cells reduces the capacity of macrophages to clear other dead cells. Altogether, these data

support that macrophages in the lungs of severe COVID-19 patients may also fail in their

efferocytic capacity.

Efferocytosis is impaired in monocytes from hyperinflammatory COVID-19 patients

Because inflammatory mediators can reduce the expression of efferocytic receptors and the

uptake of apoptotic cells (Banerjee et al., 2010; Feng et al., 2011; Michlewska et al., 2008;

Olagnier et al., 2011; Thorp et al., 2011), we also investigated if COVID-19 manifestation in the

efferocytic potential of blood monocytes. We profiled the monocyte population in blood samples

from 26 moderate to severe patients on the day of hospitalization (**Table S2**). Assessment of

circulating cytokines confirmed higher IL-6, IL-8, IL-10, and IL-1β in this cohort of patients

(**Fig. S3A**)(Lucas et al., 2020; Rodrigues et al., 2020). We observed an increase in the absolute

numbers of circulating monocytes and the proportion of monocytes among total leukocytes in

COVID-19 patients when compared to healthy control (HC) volunteers (**Fig. S3C-D**), as

described (Lucas et al., 2020). These cells also expressed less human leukocyte antigen DR

isotype (HLA-DR) on their surface (**Fig. S3D**), as described (Lucas et al., 2020; Schulte-

Schrepping et al., 2020). We observed changes in monocytes subsets in COVID-19 patients, with

an increase in the percentage of intermediate, inflammatory monocytes (CD14^{hi} CD16$^+$) and a

reduction in non-classical, anti-inflammatory monocytes (CD14^{low} CD16$^+$) that execute

efferocytosis more efficiently (**Fig. S3F-H**), similar to other observations (Hamers et al., 2019;

Schulte-Schrepping et al., 2020; Silvin et al., 2020). We then assessed the expression of CD36, a

lipid-binding receptor with an affinity for anionic phospholipids such as PtdSer exposed on

dying cells (Parks et al., 2013; Tait and Smith, 1999), and found reduced surface expression on

CD14$^+$ monocytes of COVID-19 patients, compared to healthy controls (**Fig. S3I**).

We next recovered the PBMC blood fraction from 42 COVID-19 patients by density gradient

separation and evaluated the expression of efferocytic receptors by qPCR (**Tables S2**). We found

a reduced transcription of *CD36*, *SRA-I*, *ITGB5,* and *TIMD4*, but not *MERTK*, in PBMC from

COVID-19 patients compared to HC (**Fig. 4E**). Importantly, such a pattern was not observed in

PMBC isolated from the blood of patients with acute respiratory distress syndrome unrelated to

COVID-19 (**Table S3**) and admitted to the same hospital facility at the time of this study (**Fig.**

4F). We then addressed a possible association between the levels of efferocytic receptors (**Fig.**

4E) and the worsening of COVID-19. To that end, we stratified these COVID-19 patients

according to their hyperinflammatory state at hospital admission, based on a score of clinical

criteria (fever, macrophage activation, hematological dysfunction, coagulopathy, hepatic injury,

and cytokinaemia) that defines COVID-19-associated hyperinflammation (cHIS score) (Webb et

al., 2020). We found a statistically significant reduction in the expression of *CD36*, *TIMD4,* and

SRA-I for patients with a cHIS score of at least 2, which is associated with worsening in severity

and risk of death (Webb et al., 2020) (**Fig. 4G**).

Finally, we assessed the uptake of dying cells by monocytes from COVID-19 patients. We

stimulated monocytes obtained from PBMC samples from COVID-19 patients with apoptotic

cells and evaluated their phagocytic activity by epifluorescence microscopy. We found that

monocytes from COVID-19 patients with cHIS score > 2 were less efficient in the uptake of

dying cells (**Fig. 4H**). This failure was not caused by an intrinsic defect in phagocytosis, as

monocytes from HC and COVID-19 patients internalized zymosan similarly (**Fig. S3J**).

Thus, monocytes from severe COVID-19 patients that develop hyperinflammation express lower

levels of efferocytic receptors and are less efficient in the clearance of dying cells.

Discussion

In summary, we demonstrate that the sensing and engulfment of SARS-CoV-2-infected dying

cells by macrophages switches the effector response to efferocytosis from a potential wound

healing, anti-inflammatory function to a pro-inflammatory one. Our data supports that the uptake

of cell corpses infected with SARS-CoV-2 exacerbates the secretion of inflammatory IL-6 and

IL-1β, suggesting a mechanism for the robust secretion of cytokines related to COVID-19

cytokine storm. Another important consequence of this shift in macrophage function is the

impairment of macrophage capacity to engulf apoptotic cells continually and promote proper

injury resolution. Instead, our data suggest that efferocytosis of infected cells may augment

tissue damage by causing inefficient clearance of dead cells. This process may consequently

contribute to respiratory complications developed by patients with the severe form of the disease

and increase susceptibility to secondary bacterial infections for the lack of effective disease

tolerance mechanisms that restrain collateral tissue damage (Jamieson et al., 2013). While such

causal connection remains to be investigated, our histological assessment and reanalysis of

scRNAseq datasets suggest that the efferocytic capacity of lung macrophages is impaired in the

lungs of COVID-19 patients. We further demonstrate that circulating monocytes of COVID-19

patients with hyperinflammation present reduced expression of efferocytic receptors and fail to

uptake dying cells. While our data is suggestive of a loop between dysfunctional macrophage

responses upon the uptake of infected cell corpses in the lungs and signaling affecting efferocytic

capacity of blood monocytes, follow-up studies are necessary to establish how COVID-19-

associated hyperinflammation impairs the efferocytic machinery in circulating cells. Still,

macrophage function in tissue repair and remodeling should be further compromised by the loss

of efferocytic potential in infiltrating monocytes.

In the context of COVID-19 immunopathogenesis, excessive amounts of necrotic cells may lead

to high levels of circulating DAMP, such as HMGB1 and lactate dehydrogenase (LDH), both of

which correlate with disease severity (Chen et al., 2020; Han et al., 2020; Rodrigues et al., 2020).

It is thus possible that the combination of exacerbated cytokine production and interruption of

continual efferocytosis in response to engulfment of SARS-CoV-2-infected corpses could both

increase the magnitude and duration of inflammation, contributing to the hyperinflammatory

state and multiorgan damage in COVID-19. Finally, recent studies reported higher levels of

autoantibodies (such as against IFNγ, phospholipids, and annexin A2) in COVID-19 patients

(Bastard et al., 2020; Zuniga et al., 2021; Zuo et al., 2020), suggesting that autoantibodies may

drive the worsening of the disease. It has long been known that defective engulfment or

processing of dying cells causes the development of autoimmune diseases (Boada-Romero et al.,

2020; Cohen et al., 2002; Miyanishi et al., 2007; Peng and Elkon, 2011; Rodriguez-Manzanet et

al., 2010). In light of our findings, perhaps defective clearance of apoptotic cells caused by

SARS-CoV-2 infection and SARS-CoV-2-loaded ACs also contributes to COVID-19-associated

autoimmunity.

As it becomes clear that COVID-19 is a disease of immune dysfunction (Cohen et al., 2002),

antivirals, and other therapeutic efforts to limit viral replication may fail to benefit critically ill

patients. In those patients, successful therapeutic strategies may rely on targeting dysregulated

components of the host response to limit damage to the host, thus promoting disease tolerance

and stimulating a resolutive response that restores homeostasis. In this context, our study

provides important insights into the mechanisms driving the pathophysiology of COVID-19 that

can be explored in the design of therapeutics approaches toward harnessing innate immune

responses and macrophage function during SARS-CoV-2 infection.

Material and Methods

Study approval. The procedures followed in the study were approved by the Research Ethics

Committee of Hospital das Clínicas de Ribeirão Preto (CEP-FMRP/USP) and by the National

Ethics Committee, Brazil (Comissão Nacional de Ética em Pesquisa (CONEP), protocols

30248420.9.0000.5440 and 39722020.9.0000.5440. Written informed consent was obtained from

recruited patients.

Patient samples. A total of 59 patients with COVID-19 and 10 patients with non-COVID-19

acute respiratory distress syndrome admitted in the Hospital das Clínicas de Ribeirão Preto from

April to August 2020 were enrolled in this study. SARS-CoV-2 infection was confirmed by RT-

PCR of swab samples, as previously described (Corman et al., 2020). Patients were classified

according to their clinical manifestations in (1) mild cases, in which there were mild clinical

symptoms and no pneumonia was found in imaging; (2) moderate cases, characterized by fever,

respiratory tract symptoms, and pneumonia identifiable by imaging; and (3) severe cases,

meaning adults who met any of the following features: arterial partial pressure of oxygen

(PaO_2)/oxygen concentration (FiO_2) <300 mm Hg, oxygen saturations at 93% at a rest state and

respiratory rate > 30 breaths/min. **Table S2** describes clinical, laboratory, and treatment records

of COVID-19 patients. **Table S3** describes clinical, laboratory, and treatment records of non-

COVID-19 patients admitted with acute respiratory distress syndrome. Samples from healthy

donors tested negative for COVID-19 using RT-PCR or tested negative using serology (specific

IgM and IgG antibodies; Asan Easy Test COVID-19 IgM/IgG kits, Asan Pharmaceutical Co.)

were used as controls or for isolation of monocytes for in vitro studies.

Isolation of human peripheral blood mononuclear cells, monocyte seeding, and

macrophage differentiation. Peripheral blood mononuclear cells (PBMC) from healthy donors

and COVID-19 patients were isolated from peripheral blood collected in tubes containing EDTA

(BD Vacutainer, BD Biosciences). The samples were centrifuged at 400 *g* for 10 min at room

temperature (RT), the plasma was discarded, and the cellular portion was diluted in phosphate-

buffered saline (PBS). PBMC were isolated by density–gradient centrifugation using

Histopaque-1077 (Sigma-Aldrich). The collected PBMC fraction was treated with ACK lysis

buffer to lyse erythrocytes and washed twice with PBS. For qRT-PCR, cell lysis proceeded as

described below. To obtain monocyte cultures, PBMC were plated on 24-well plates for 1h in

serum-free RPMI 1640 (GIBCO) at 37°C in a 5% CO_2 atmosphere for monocyte adhesion. The

cells were then washed three times with PBS, followed by media replenishment with RPMI1640

media supplemented with penicillin (10.000 U/mL, GIBCO), streptomycin (10.000 μg/mL,

GIBCO), 1% glutamine (GIBCO), and 10% heat-inactivated human serum (Sigma Aldrich). For

macrophages differentiation, monocytes were cultivated for 7 d in RPMI 1640 supplemented

with human serum.

Cell Lines. Calu-3, Vero CCL81, Jurkat, and THP-1 cells were from (ATCC®). Calu-3 and Vero

CCL81 cells were maintained in DMEM with 4.5 g/L glucose (GIBCO) supplemented with

penicillin (10.000 U/mL), streptomycin (10.000 μg/mL), and 10% heat-inactivated fetal bovine

serum (FBS, GIBCO) (DMEMc) at 37°C in a 5% CO_2 atmosphere. Jurkat cells and THP-1 cells

were maintained in RPMI1640 media supplemented with penicillin (10.000 U/mL), streptomycin

(10.000 μg/mL), 1% glutamine, and 10% FBS (RPMIc) at 37°C in a 5% CO_2 atmosphere.

THP-1-derived macrophages were obtained by treatment with phorbol 12-myristate 13-acetate

(PMA, 50 ng/mL, Sigma-Aldrich) for 24 h, followed by media replenishment with fresh RPMIc

and other 24 h incubation period before stimulation.

Cell lines were routinely screened for mycoplasma contamination, and all cell lines tested

negative.

Viral stock. The SARS-CoV-2 strain (Brazil/SPBR-02/2020) was isolated from the first

Brazilian case of COVID-19. The viral stock was produced in a monolayer of Vero CCL81 cells

maintained in serum-free DMEM at 37°C in a 5% CO_2 atmosphere. Coxsackievirus B5

(Coxsackie) was originally shared by Dr. Roger M. Loria (Virginia Commonwealth University,

Richmond, Virginia, USA) (Gomes et al., 2009). The viral stock was produced in a monolayer of

HeLa cells maintained in DMEM supplemented with 2% FBS at 37°C and 5% CO_2. Viral stocks

were propagated under BSL3 conditions and stored at -80°C. Viral loads were estimated by

titration in Vero CCL81 cells seeded onto 96-well plates and standard limiting dilution to

confirm the 50% tissue culture infectious dose.

Isolation of apoptotic cells. To generate SARS-CoV-2-infected apoptotic cells (CoV2-AC)

from Vero CCL81 and Calu-3 cultures, or Coxsackievirus B5-infected apoptotic cells

(Coxsackie-AC) from Vero CCL81 cultures, cell monolayers were rinsed with PBS, replenished

with a thin layer of serum-free media, and infection with a freshly thawed virus aliquot at a

multiplicity of infection (MOI) of approximately 0.05 was carried out for 1 h at 37°C and 5%

CO_2 for viral adsorption. The cells were then topped with fresh media and incubated for 48 h.

Sterile apoptotic cells (UV-AC) were generated by exposure to UV-C radiation (Calu-3 cells at

500 mJ/cm^2 and Vero CCL81 cells at 350 mJ/cm^2) in a UV crosslinker (Fisher Scientific),

followed by 6h incubation in DMEMc at 37°C and 5% CO_2. At the established time points, the

supernatants were collected and temporarily stored for further processing. Then, a suspension

containing CoV2-AC or UV-AC was obtained by carefully pipetting fresh media up and down

the plate surface and collecting loosely attached cells. Following spun at 300 *g* for 5 min,

pelleted AC were washed with PBS, resuspended in fresh media, and counted with a Neubauer

chamber prior to incubation with macrophages.

For virus inactivation, isolated AC suspension was placed onto tissue culture hood surface with

an open lid for 20 min with the UV-C lamp on. Virus inactivation was confirmed by $TCID_{50}$, as

described below. Alternatively, isolated AC were fixed with 2% paraformaldehyde (PFA) in PBS

for 10 min and washed twice with PBS before adding to macrophage cultures.

To prepare the cell-free conditioned supernatants of the infected AC (CoV2-AC Sup), collected

supernatants were spun at 300 g for 5 min to remove cellular debris; the resulting supernatant

was filtered using a 0.22 μm syringe filter and immediately used for macrophage stimulation.

The volume of CoV2-AC Sup used to stimulate macrophages was normalized to the amount of

collected AC.

Cell death assays. Cells were collected 48 hours post-infection or 6 hours post-irradiation, spun

at 300 g for 5 min, washed with PBS, and resuspended in the appropriate buffer before labeling.

Detection of PtdSer was performed by annexin-V labeling (APC annexin-V, BD Biosciences,

1:100). 10^6 cells were resuspended in annexin V binding buffer (0.01M HEPES, 0.14M NaCl,

2.5 mM CaCl2, pH 7.4), and labeling was carried out for 15 min on ice. The cells were then

fixed with 2% PFA in binding buffer for 10 min and washed before flow cytometric analyses.

For the analysis of cleaved caspase-3, infection of Calu-3 cells was carried out in the presence of

Z-VAD-FMK (Selleckchem, Houston, USA) at 20 μM, or mock treatment with vehicle (DMSO),

added to cell cultures after virus adsorption. 10^6 collected cells were washed with PBS, and

fixation, permeabilization, and staining were carried out using BD Cytofix/Cytoperm™

Fixation/Permeabilization Kit (BD Biosciences), following the manufacturer's instructions.

Immunolabelling of intracellular active caspase-3 was performed with anti-cleaved caspase-3

(Asp175) (Clone 5A1E; #9664; Cell Signaling, 1:400) and secondary donkey anti-rabbit IgG

conjugated to Alexa Fluor 488 (AF488, Molecular Probes, 1:2500).

Flow cytometric acquisitions were performed in a FACSVerse (BD Biosciences, San Jose, CA,

USA) flow cytometer.

TCID$_{50}$ quantification of viable viral particles. 10^6 isolated CoV2-AC and their equivalent

purified conditioned supernatants, obtained as described above, were lysed by snap freeze-and-

thaw. To estimate viral load in apoptotic cells isolated by annexin V labeling, all infected cells

were collected, centrifuged at 300 g for 5 min, followed by magnetic separation with annexin V

MicroBeads (Miltenyi Biotec) according to the manufacturer's protocol. 10^6 pre-sorted cells,

annexin$^+$ cells, and annexin$^-$ cells were lysed by freeze-and-thaw for quantification. Viral loads

were estimated by titration in Vero CCL81 cells seeded onto 96-well plates and expressed as

50% tissue culture infectious dose (TCID$_{50}$). Quantification was performed with the Reed-

Muench method and plotted as TCID$_{50}$ units per mL(REED and MUENCH, 1938)

***In vitro* assays with THP-1- and PBMC-derived macrophages.** 10^6 THP-1- and PBMC-

derived macrophages seeded on 24-well tissue culture plates were rinsed with warm PBS before

stimulation. Macrophage cultures were then topped with UV-AC, CoV2-AC, or Coxsackie-AC

resuspended in the appropriate serum-containing macrophage media at a 1:1 ratio. For

stimulation with conditioned supernatants, CoV2-AC-Sup were added directly to macrophages

cultures and topped with fresh media for volume adjustment. Infection with SARS-CoV-2 or

Coxsackie virus was carried out with virus adsorption at MOI 1 in serum-free media for 1 h

before topping with fresh serum-containing media. To block AC ligation and efferocytosis,

CoV2-AC were pre-incubated with 0.1 or 0.01 μg/mL of annexin-V (BD Biosciences) following

the manufacturer's recommendations prior to incubation with macrophages. To block AC

internalization, macrophages were pre-treated for 30 min, and incubation was carried out in the

presence of Cytochalasin D (10μM, Sigma). Macrophage cultures were rinsed out 2h after

incubation to remove unbound AC, topped with fresh media, and stimulation was carried on up

to supernatant collection to dose cytokines. At the time points described in the legend of the

figures, macrophages were rinsed at least twice with warm PBS to remove cell debris before

proceeding to analysis.

For gene expression analysis by RT-qPCR, rinsed macrophage cultures were lysed in appropriate

lysis buffer, as described below, and immediately frozen at -80°C.

To estimate CD206 surface expression, rinsed macrophages were removed with a cell scraper,

spun at 300 g for 5 min, washed with PBS, followed by incubation with rat serum (1:2000) for 5

min at room temperature (RT) and cell surface staining for 15 minutes at 4°C. Cells were labeled

with Zombie Violet™ Fixable Viability Kit (Biolegend) and anti-CD206-FITC antibody (clone

19.2, BD Biosciences). The cells were then fixed with 2% PFA for 10 min and washed before

flow cytometric analyses in a FACSVerse (BD Biosciences) flow cytometer.

For immunofluorescence imaging of efferocytosis, human monocyte-derived macrophages

seeded onto 13mm round coverslips were incubated with UV-AC or CoV2-AC labeled with 5

µM CellTrace™ CFSE dye (Thermo Scientific) for 2h. After rinsing out non-engulfed AC,

macrophages were fixed for 20 min with PBS 2% PFA at room temperature (RT). Cells were

then permeabilized with 0.1% Triton-X-100 in PBS for 10 min at room temperature (RT). Next,

cells were rinsed twice in PBS and incubated with PBS 1% bovine serum albumin (BSA) and 5

µg/mL normal donkey IgG (Jackson ImmunoResearch) for 45 min RT prior to overnight (ON)

incubation at 4ºC with primary antibodies: rabbit polyclonal anti-SARS-CoV-2 spike

glycoprotein antibody (ab272504 – Abcam, 1:1000) and Mouse mAb anti-Rat CD11b (clone

OX42; ab1211, Abcam, 1:300) diluted in PBS containing 1% BSA. Next, coverslips were

washed with PBS, and the following secondary antibodies were used for immunofluorescence:

Next, cells were rinsed thoroughly in PBS and incubated for 30 min at RT with the secondary

antibodies diluted in PBS: donkey anti-rabbit IgG F(ab)´$_2$-Alexa 594 (1:1000; Thermo Fisher

Scientific) and donkey anti-mouse IgG F(ab)´$_2$-Alexa 647 (1:1000; Thermo Fisher Scientific).

Cell nuclei were stained with Hoechst 33342. Cells were then rinsed, and coverslips mounted on

glass slides with Fluoromount-G (Invitrogen). Samples were analyzed using a Zeiss LSM 780

laser scanning confocal microscope (Carl Zeiss).

For the engulfment assays by flow cytometry, macrophages were labeled with 5 µM CellTrace™

Violet dye (CTV, Thermo Scientific), according to the manufacturer's recommendations.

CellTrace™ Violet (CTV)-labeled macrophages were stimulated with UV-AC or CoV2-AC

previously stained with 1 µM CellTrace™ Far Red dye (CTFR, Thermo Scientific), or 5 µM

CellTrace™ CFSE dye, as described in the legend of the figures. Following the removal of

unbound AC, macrophages were collected with a cell scraper, fixed with 2% PFA for 10 min,

and washed before proceeding with the acquisition by flow cytometry. For the two-round

efferocytosis assay, first-round UV-AC and CoV2-AC were labeled with a pH indicator

fluorogenic intracellular probe (pHrodo Red AM Intracellular pH Indicator - Thermo Scientific).

Second-round apoptotic Jurkat cells (UV-Jurkat) were generated by UV-C irradiation at 20

mJ/cm^2, followed by labeling with 1 µM CTFR and incubation at 37°C and 5% CO_2 for 6h.

CTV-labelled THP-1 cells were incubated with pHrodo-UV-AC or pHrodo-CoV2-AC for 18h at

a 1:1 ratio. Cells were then rinsed three times with PBS to remove non-engulfed AC, and CTV-

labelled Jurkat-AC were added to the culture at a 1:1 ratio for 2h. Macrophage cultures were

collected with a cell scraper, washed, fixed with 2% PFA for 10 min, and washed before

proceeding with the acquisition by flow cytometry. Flow cytometric acquisition was performed

in a FACSVerse (BD Biosciences) flow cytometer.

Phenotyping of blood monocytes. Blood samples from healthy donors and COVID-19 patients

were processed for erythrocyte lysis with ACK buffer, followed by incubation with Fc blocking

(BD Pharmingen) for 5 min at RT and labelling with monoclonal antibodies for CD14 (clone

M5E2; BD Pharmingen^{TM}), CD16 (clone ebioCB16(CB16); eBioscience Inc., San Diego; USA),

CD36 (clone CB38; BD Pharmingen^{TM}), HLA-DR (clone L243; BD Pharmingen^{TM}), CD3 (clone

SK7; BD Pharmingen^{TM}), CD19 (clone 6D5; BD Pharmingen^{TM}), CD56 (clone NCAM16.2; BD

Pharmingen^{TM}) and Fixable Viability Dye eFluor 780 (eBioscience) for 30 min at 4°C. The cells

were then washed with PBS and fixed with 2% PFA for 10 min before analyses in a FACSVerse

(BD Biosciences) flow cytometer.

***In vitro* efferocytosis assay with monocytes from COVID-19 patients.** 10^6 PBMC from

healthy donors or COVID patients were plated onto eight-well chamber slides (Tek Chamber

Slide, Thermo Scientific) for monocyte adherence, followed by 24h incubation in RPMI

supplemented with 10% heat-inactivated human serum before stimulation. For induction of

apoptosis in thymocytes, cells isolated from C57BL/6 mice were resuspended in DMEMc and

treated with 20 mJ/cm^2 ultraviolet C irradiation and incubated for 6h at 37°C in a 5% CO_2.

Monocytes were incubated with apoptotic thymocytes at 1:5 ratio for 1h or zymosan A particles

(Thermo Scientific) at 1:1 ratio for 20 min at 37°C and 5% CO_2. The cells were then washed

with PBS at least three times to remove unbound apoptotic cells and zymosan particles, followed

by fixation with 4% PFA PBS solution for 15 min and rinsed twice with 0.01% Tween-20 Tris-

buffered saline (TBS). After permeabilization (0.1% Triton-X-100 in TBS for 3 min at RT), cells

were labeled with phalloidin conjugated to Alexa Fluor 488 (Thermo Scientific) and Hoechst

33342, and coverslips mounted with Fluoromount-G. Immunofluorescence and phase-contrast

images were acquired with 40x objective lens of Leica DMI4000B microscope (Leica

Microsystems; Heidelberg, Germany). To quantify AC engulfment, monocytes were identified

by nuclei morphology and membrane boundary, and AC uptake was enumerated using nuclei

fragmentation in the internalized thymocytes and transient F-actin reorganization around the

engulfed AC as criteria (Mylvaganam et al., 2021; Satyanarayanan et al., 2019). Quantification

was performed by the same researcher blinded to sample identification, and at least 10 fields and

minimum 30 cells were counted per sample. Phagocytic index, as a normalization by the average

percentage of uptake in control samples, was used to account for inherited differences between

experiments performed on different days. The representative images were obtained using a Zeiss

LSM 780 laser scanning confocal microscope (Carl Zeiss, Heidelberg, Germany).

Cytokine quantification. IL-6 and IL-1β cytokine levels in macrophage supernatants were

evaluated by ELISA assay (R&D Systems, Minneapolis, MN, EUA) or BD™ Cytometric Bead

Array (CBA) (#551811, BD Biosciences), as indicated in the legend of the figures, following the

manufacturers' recommendations. The cytokine levels in culture supernatants were evaluated by

CBA. IL-1β, IL-6, IL-8, IL-10, IL-12, and TNF-α detection in serum from healthy donors and

patients with COVID-19 were performed with CBA.

RNA isolation and gene expression analyses. Total RNA extraction of PBMC from healthy

donors or COVID-19 patients was performed using PureLink™ RNA Mini Kit (Ambion Inc.,

ThermoFisher Scientific), following the manufacturer's recommendations. Reverse transcription

was performed using the High Capacity cDNA Reverse Transcriptase Kit (Applied

Biosystems™, Foster City, USA), following the manufacturer's recommendations.

Total RNA extraction for human monocyte- or THP-1-derived macrophages stimulated *in vitro*

was performed using Directzol™ RNA miniPrep Kit (Zymo Research, Irvine, CA, USA),

following the manufacturer's recommendations. Reverse transcriptase was performed using M-

MLV reverse transcriptase (ThermoFisher Scientific) according to the manufacturer's

recommendations.

Gene expression RT-qPCR was performed using SybrGreen Master Mix (Applied Biosystems).

RT-qPCR was performed in fast mode, following the manufacturer's recommendations. The

589   evaluation of each gene expression was determined by the comparative CT method. Primer

590   sequences used were:

Gene	5' Forward	3' Reverse
CCL18	CTCTGCTGCCTCGTCTATACCT	CTTGGTTAGGAGGATGACACCT
CD163	GCGGGAGAGTGGAAGTGAAAG	GTTACAAATCACAGAGACCGCT
CD36	GGGAAAGTCACTGCGACATG	TGCAATACCTGGCTTTTCTCA
GAPDH	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA
IL6	GGTACATCCTCGACGGCATCT	GTGCCTCTTTGCTGCTTTCAC
ITGB5	AACCAGAGCGTGTACCAGAA	AGGAGAAGTTGTCGCACTCA
MERTK	CTCTGGCGTAGAGCTATCACT	AGGCTGGGTTGGTGAAAACA
MMP9	TGTACCGCTATGGTTACACTCG	GGCAGGGACAGTTGCTTCT
MRC1	AGCCAACACCAGCTCCTCAAGA	CAAAACGCTCGCGCATTGTCCA
PPARγ	ACCAAAGTGCAATCAAAGTGGA	ATGAGGGAGTTGGAAGGCTCT
SRA-1	GCAGTGGGATCACTTTCACAA	AGCTGTCATTGAGCGAGCATC
TIM4	ACAGGACAGATGGATGGAATACCC	AGCCTTGTGTGTTTCTGCG

Histological analysis. Ultrasound-guided minimally invasive autopsies for COVID-19 deceased

patients were approved by the Research Ethics Committee of Hospital das Clínicas de Ribeirão

Preto (CEP, protocol no. 4.089.567). Non-neoplasic sections of lung parenchyma were obtained

from lobectomies for lung cancer as a control group (Rodrigues et al., 2020). Paraffin sections

from lungs were collected and processed as previously described (Rodrigues et al., 2020).

Sections were rinsed in PBS, and the antigen retrieval was performed by incubation of samples

with 0.1% trypsin (ThermoFisher Scientific) in PBS at 37ºC for 15 min. Next, sections were

rinsed and incubated with Image-iT FX Signal Enhancer (ThermoFisher Scientific) for 30 min at

RT. Sections were then rinsed in PBS and incubated for 45 min at RT in PBS containing 0.5%

BSA and 5µg/mL normal donkey IgG (Jackson ImmunoResearch).

For analysis of active caspase 3, lung sections were labeled with primary antibodies diluted in

PBS and incubated overnight ON at 4ºC: rabbit polyclonal anti-human cleaved caspase 3

(Asp175) (Clone 5A1E; #9664; Cell Signaling; 1:1000) and mouse anti-dsRNA (1:1000). Then,

sections were rinsed thoroughly in PBS and incubated for 45 min at RT with the secondary

antibodies: donkey anti-rabbit IgG conjugated to Alexa 594 (1:500; Thermo Fisher Scientific)

and donkey anti-mouse IgG F(ab)´$_2$-Alexa 488 (1:500; Thermo Fisher Scientific) diluted in PBS.

Sections were then rinsed, and coverslips mounted with DAPI Fluoromount-G (EM Sciences).

For *in situ* efferocytosis analysis, lung sections were labeled with primary antibodies diluted in

PBS and incubated overnight ON at 4ºC: mouse mAb anti-human CD68 (Clone KP1; Dako;

1:100), rabbit mAb anti-human cytokeratin 18 (Clone N1N3; GeneTex, 1:500) and anti-Spike

(rabbit polyclonal anti-SARS-CoV-2 Spike glycoprotein antibody, ab272504 – Abcam; 1:80)

previously conjugated to FITC (FITC Conjugation Kit-Lightning-Link®, Abcam, according to

the manufacturer's instructions). Then, sections were rinsed thoroughly in PBS and incubated for

45 min at RT with the secondary antibodies: donkey anti-rabbit IgG conjugated to Alexa 594

(1:500; Thermo Fisher Scientific) and donkey anti-mouse IgG F(ab)´$_2$-Alexa 647 (1:500; Thermo

Fisher Scientific) diluted in PBS. Next, sections were incubated for 15 min at RT with Hoechst

33342 (Invitrogen), rinsed in PBS, and mounted on glass slides with Fluoromount-G

(Invitrogen). Samples from active caspase 3 and *in situ* efferocytosis experiments were analyzed

using an ECLIPSE Ti2 Series microscope (Nikon).

For CD36 or MERTK expression analysis, lung sections were labeled with the primary

antibodies diluted in PBS and incubated overnight ON at 4ºC: rabbit polyclonal anti-human

CD36 (PA5-81996; 1:100 ThermoFisher Scientific) or rabbit mAb anti-human MERTK (Clone

SR29-07; 1:150; ThermoFisher Scientific) and mouse mAb anti-human calprotectin (Clone

MAC387; MA1-81381; 1:100; ThermoFisher Scientific). Then, sections were rinsed thoroughly

in PBS and incubated for 45 min at RT with the secondary antibodies donkey anti-rabbit IgG

conjugated to Alexa 488 (1:500; Thermo Fisher Scientific) and goat anti-mouse IgG conjugated

to Alexa 594 (Jackson ImmunoResearch) diluted in PBS. Sections were then rinsed, and

coverslips mounted with DAPI Fluoromount-G. Samples were analyzed using an Olympus BX61

Fluorescence Motorized Slide Scanner Microscope Pred VS120 (Olympus, Hamburg, Germany).

Re-analysis of scRNA-seq Data. We re-analyzed single-cell transcriptomic data from

bronchoalveolar lavage fluid (BAL) from patients with varying severity of COVID-19 disease

and their respective healthy controls (Liao et al., 2020). The dataset is publicly available at

https://covid19-balf.cells.ucsc.edu/. Downloaded data was imported into R environment version

v3.6.3. Differential expression analysis was conducted using FindMarkers function in Seurat

using the Wilcoxon test to compare mild and severe COVID-19 patients with healthy individuals

for each cluster previously identified by authors. Differentially expressed genes between

mild/severe COVID-19 patients and controls for each cluster were identified considering genes

expressed in at least 5% of cells and FDR < 0.05 and |avg_logFC| > 0.1. In addition, a

differentially expressed gene list comparing infected (identified SARS-Cov-2 transcripts) against

non-infected alveolar macrophages were obtained from supplemental materials from (Ren et al.,

2021). Gene Set Enrichment Analysis (GSEA) was performed using ClusterProfiler and fgsea R

packages (Korotkevich et al., 2021; Wu et al., 2021) for each differentially expressed gene or

log2 fold-change lists from Liao et al. (2020) and Ren et al. (2021) dataset. A custom gene set

was also utilized as a reference for GSEA, incorporating GO:0006911, GO:0043277 gene

ontology terms, and additional efferocytic related genes from the literature (Penberthy and

Ravichandran, 2016; Boada-Romero et al., 2020) (**Table S1**). Significantly enriched sets were

identified considering terms with p-value < 0.05.

Data processing, quantification, and statistical analyses. Flow cytometric data processing was

performed using FlowJo_V10 software (BD Biosciences). Images obtained by confocal and

epifluorescence microscopy were analyzed using ImageJ (NIH). Data were plotted and analyzed

with GraphPad Prism 8.4.2 software (GraphPad Prism Software Inc., San Diego, CA). The

statistical tests used are listed in the legend of the figures. For the *in vitro* assays, we used

Student's t-test to compare two experimental groups or one-way ANOVA, followed by ordinary

ANOVA and multiple comparison correction, to compare three or more experimental groups.

For the comparison between COVID-19 patients and healthy control datasets, normality tests

were performed, and samples with non-Gaussian distribution were analyzed applying the Mann–

Whitney test. For monocyte phenotyping from blood samples, the outliers were identified

applying the ROUT method defining Q = 0.1% and then removed from the analyses. *p* values <

0.05 were considered significant.

Acknowledgements

The authors thank Denise M. da Fonseca, Elizabete R. Milani and Roberta R. C. Rosales

(FMRP-USP) for technical assistance and Jennifer Martinez (NIEHS, NIH) for thoughtful

insights and discussions.

Funding: This work was supported by grants from:

Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) grants

2018/25559-4 and 2020/05288-6 (L.D.C)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) grant

88887.507253/2020-00 (D. S. Z. and L.D.C.)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grant

434538/2018-3 (L.D.C.)

D.S., A. C. G. S., T. S. R. are supported by FAPESP fellowships.

Author Contributions

Conceptualization: A. C. G. S., D. S., T. S. R., and L.D.C.

Methodology: A. C. G. S., D. S., T. S. R. and L.D.C

Investigation and data analysis: A. C. G. S., D. S., T. S. R.

Investigation and data analysis – specific experiments: M. F. R., E. G. F. F., D. L. A. T.,

M. H. F. L., D. B. C. N., and I. M. S. C.

Clinical data curation: N. B. A., M. C. G., L. P. B., M I. F. L., M. N. B., S. S. B., R. C. S.,

F. C. V., M. A. M., R. L. A., S. C. L. A, F. R. O., A. T. F., P. L. J. and R. D. R. O

Clinical data analysis: P. L. J. and R. D. R. O

Resources: C. M. S., J. E. T., A. B., S. O., D. B. C., L. A., A. Y. I , T. M. L., R. B. M., F.

V., E. A., T. M. C., J. C. A. F., A.T.F., H. I. N., D. S. Z., P. L. J. and R. D. R. O

Visualization: A.C.G.S., D. S. and I. C.

Funding acquisition and supervision: L. D. C.

Writing – original draft: D. S., A. C. G. S., T. S. R., and L. D. C

Writing – review and editing: all authors

Competing Interests

The authors declare no competing financial interests.

Data Availability

All data are available in the main text or supporting information.

References

704
705

A-Gonzalez N, Quintana JA, García-Silva S, Mazariegos M, Aleja AG de la, Nicolás-Ávila JAA,
Walter W, Adrover JM, Crainiciuc G, Kuchroo VK, Rothlin CV, Peinado H, Castrillo A,
Ricote M, Hidalgo A. 2017. Phagocytosis imprints heterogeneity in tissue-resident
macrophages. *The Journal of experimental medicine* 214:1281–1296.
doi:10.1084/jem.20161375
Banerjee S, Friggeri A, Liu G, Abraham E. 2010. The C-terminal acidic tail is responsible for the
inhibitory effects of HMGB1 on efferocytosis. *J Leukocyte Biol* 88:973–979.
doi:10.1189/jlb.0510262
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, Dorgham K, Philippot
Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L,
Trouillet-Assant S, Dobbs K, Jesus AA de, Belot A, Kallaste A, Catherinot E, Tandjaoui-
Lambiotte Y, Pen JL, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN,
Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar
K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-
Murci L, Beek D van de, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-
Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G,
Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen J, Biondi A, Bettini LR, D'Angio M,
Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV,
Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari
A, Marseglia GL, Duval X, Ghosn J, Lab§ H, Group§ N-UIR to C, Clinicians§ C, Clinicians§
C-S, Group§ IC, Group§ FCCS, Consortium§ TMI, Cohort§ C-C, Biobank§ AUC-19, Effort§
CHG, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang S-Y, Holland
SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC,
Casanova J-L. 2020. Auto-antibodies against type I IFNs in patients with life-threatening
COVID-19. *Science* eabd4585. doi:10.1126/science.abd4585
Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi
K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. 2020.

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*
181:1036-1045.e9. doi:10.1016/j.cell.2020.04.026
Boada-Romero E, Martinez J, Heckmann B, Green D. 2020. The clearance of dead cells by
efferocytosis. *Nat Rev Mol Cell Bio* 1–17. doi:10.1038/s41580-020-0232-1
Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-
Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, Rothlin CV.
2017. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with
apoptotic cells. *Sci New York N Y* 356:1072–1076. doi:10.1126/science.aai8132
Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC-Y, Chan W-M, Fan Z, Tsoi
H-W, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai J-P, Kok K-H, Chu H, Chan K-H,
Sridhar S, Chen Z, Chen H, To KK-W, Yuen K-Y. 2020. Simulation of the Clinical and
Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian
Hamster Model: Implications for Disease Pathogenesis and Transmissibility. *Clin Infect Dis*
Official Publ Infect Dis Soc Am 71:2428–2446. doi:10.1093/cid/ciaa325
Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, Wei J, Luo H, Zhu H, Huang Liang, Meng F,
Huang Lifang, Wang N, Zhou X, Zhao L, Chen X, Mao Z, Chen C, Li Z, Sun Z, Zhao J,
Wang D, Huang G, Wang W, Zhou J. 2020. Elevated serum levels of S100A8/A9 and
HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19
patients. *Cell Mol Immunol* 17:992–994. doi:10.1038/s41423-020-0492-x
Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S, Wang Y, Hu B, Yip CC-Y, Tsang JO-L,
Huang X, Chai Y, Yang D, Hou Y, Chik KK-H, Zhang X, Fung AY-F, Tsoi H-W, Cai J-P,
Chan W-M, Ip JD, Chu AW-H, Zhou J, Lung DC, Kok K-H, To KK-W, Tsang OT-Y, Chan
K-H, Yuen K-Y. 2020. Comparative tropism, replication kinetics, and cell damage profiling
of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations,
transmissibility, and laboratory studies of COVID-19: an observational study. *Lancet Microbe*
1:e14–e23. doi:10.1016/s2666-5247(20)30004-5
Chu H, Shuai H, Hou Y, Zhang X, Wen L, Huang X, Hu B, Yang D, Wang Y, Yoon C, Wong
BH-Y, Li C, Zhao X, Poon VK-M, Cai J-P, Wong KK-Y, Yeung M-L, Zhou J, Au-Yeung
RK-H, Yuan S, Jin D-Y, Kok K-H, Perlman S, Chan JF-W, Yuen K-Y. 2021. Targeting
highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease
severity. *Sci Adv* 7:eabf8577. doi:10.1126/sciadv.abf8577
Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RAS, Earp HS,
Matsushima G, Reap EA. 2002. Delayed Apoptotic Cell Clearance and Lupus-like
Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine Kinase. *J Exp Medicine*
196:135–140. doi:10.1084/jem.20012094
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
Schneider J, Schmidt ML, Mulders DG, Haagmans BL, Veer B van der, Brink S van den,
Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-
time RT-PCR. *Eurosurveillance* 25:2000045. doi:10.2807/1560-7917.es.2020.25.3.2000045
Doran AC, Yurdagul A, Tabas I. 2020. Efferocytosis in health and disease. *Nat Rev Immunol*
20:254–267. doi:10.1038/s41577-019-0240-6
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. 1992. Exposure of
phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and
removal by macrophages. *J Immunol Baltim Md 1950* 148:2207–16.

Feng X, Deng T, Zhang Y, Su S, Wei C, Han D. 2011. Lipopolysaccharide inhibits macrophage
phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α
and growth arrest-specific gene 6. *Immunology* 132:287–295. doi:10.1111/j.1365-
2567.2010.03364.x
Gomes R, Guerra-Sá R, Arruda E. 2009. Coxsackievirus B5 induced apoptosis of HeLa cells:
effects on p53 and SUMO. *Virology* 396:256–63. doi:10.1016/j.virol.2009.10.005
Hamers AAJ, Dinh HQ, Thomas GD, Marcovecchio P, Blatchley A, Nakao CS, Kim C,
McSkimming C, Taylor AM, Nguyen AT, McNamara CA, Hedrick CC. 2019. Human
Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry. *Arteriosclerosis*
Thrombosis Vasc Biology 39:25–36. doi:10.1161/atvbaha.118.311022
Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, Tong C, Zha Y, Song Z, Gu G. 2020. Lactate
dehydrogenase, a Risk Factor of Severe COVID-19 Patients. *Medrxiv* 2020.03.24.20040162.
doi:10.1101/2020.03.24.20040162
Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013. Role of
Tissue Protection in Lethal Respiratory Viral-Bacterial Coinfection. *Science* 340:1230–1234.
doi:10.1126/science.1233632
Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. 2021. Fast gene
set enrichment analysis. *Biorxiv* 060012. doi:10.1101/060012
Li Shaohua, Jiang L, Li X, Lin F, Wang Y, Li B, Jiang T, An W, Liu S, Liu H, Xu P, Zhao L,
Zhang L, Mu J, Wang H, Kang J, Li Y, Huang L, Zhu C, Zhao S, Lu J, Ji J, Zhao J. 2020.
Clinical and pathological investigation of patients with severe COVID-19. *Jci Insight* 5.
doi:10.1172/jci.insight.138070
Li Shufen, Zhang Y, Guan Z, Li H, Ye M, Chen X, Shen J, Zhou Y, Shi Z-L, Zhou P, Peng K.
2020. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8
activation. *Signal Transduct Target Ther* 5:235. doi:10.1038/s41392-020-00334-0
Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I,
Zhang S, Zhang Z. 2020. Single-cell landscape of bronchoalveolar immune cells in patients
with COVID-19. *Nat Med* 26:842–844. doi:10.1038/s41591-020-0901-9
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE,
Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang
H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier
JB, Campbell M, Odio CD, Casanovas-Massana A, Obaid A, Lu-Culligan A, Nelson A, Brito
A, Nunez A, Martin A, Watkins A, Geng B, Kalinich C, Harden C, Todeasa C, Jensen C, Kim
D, McDonald D, Shepard D, Courchaine E, White EB, Song E, Silva E, Kudo E, DeIuliis G,
Rahming H, Park H-J, Matos I, Nouws J, Valdez J, Fauver J, Lim J, Rose K-A, Anastasio K,
Brower K, Glick L, Sharma L, Sewanan L, Knaggs L, Minasyan M, Batsu M, Petrone M,
Kuang M, Nakahata M, Campbell M, Linehan M, Askenase MH, Simonov M, Smolgovsky
M, Sonnert N, Naushad N, Vijayakumar P, Martinello R, Datta R, Handoko R, Bermejo S,
Prophet S, Bickerton S, Velazquez S, Alpert T, Rice T, Khoury-Hanold W, Peng X, Yang Y,
Cao Y, Strong Y, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Cruz CD,
Farhadian S, Ko AI, Omer SB, Iwasaki A. 2020. Longitudinal analyses reveal immunological
misfiring in severe COVID-19. *Nature* 584:463–469. doi:10.1038/s41586-020-2588-y
Martins R, Carlos AR, Braza F, Thompson JA, Bastos-Amador P, Ramos S, Soares MP. 2019.
Disease Tolerance as an Inherent Component of Immunity. *Annu Rev Immunol* 37:405–437.
doi:10.1146/annurev-immunol-042718-041739

Michlewska S, Dransfield I, Megson IL, Rossi AG. 2008. Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha. *Faseb J Official Publ Fed Am Soc Exp Biology* 23:844–54. doi:10.1096/fj.08-121228

Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. 2007. Identification of Tim4 as a phosphatidylserine receptor. *Nature* 450:435–439. doi:10.1038/nature06307

Morioka S, Perry JSA, Raymond MH, Medina CB, Zhu Y, Zhao L, Serbulea V, Onengut-Gumuscu S, Leitinger N, Kucenas S, Rathmell JC, Makowski L, Ravichandran KS. 2018. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. *Nature* 563:714–718. doi:10.1038/s41586-018-0735-5

Mulay A, Konda B, Garcia G, Yao C, Beil S, Villalba JM, Koziol C, Sen C, Purkayastha A, Kolls JayK, Pociask DA, Pessina P, Aja JS de, Garcia-de-Alba C, Kim CF, Gomperts B, Arumugaswami V, Stripp BR. 2021. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. *Cell Reports* 35:109055. doi:10.1016/j.celrep.2021.109055

Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol* 11:723–737. doi:10.1038/nri3073

Mylvaganam S, Freeman SA, Grinstein S. 2021. The cytoskeleton in phagocytosis and macropinocytosis. *Curr Biol* 31:R619–R632. doi:10.1016/j.cub.2021.01.036

Nagata S. 2018. Apoptosis and Clearance of Apoptotic Cells. *Annu Rev Immunol* 36:489–517. doi:10.1146/annurev-immunol-042617-053010

Olagnier D, Lavergne R-A, Meunier E, Lefèvre L, Dardenne C, Aubouy A, Benoit-Vical F, Ryffel B, Coste A, Berry A, Pipy B. 2011. Nrf2, a PPARγ Alternative Pathway to Promote CD36 Expression on Inflammatory Macrophages: Implication for Malaria. *Plos Pathog* 7:e1002254. doi:10.1371/journal.ppat.1002254

Park D, Han CZ, Elliott MR, Kinchen JM, Trampont PC, Das S, Collins S, Lysiak JJ, Hoehn KL, Ravichandran KS. 2011. Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. *Nature* 477:220–4. doi:10.1038/nature10340

Parks BW, Black LL, Zimmerman KA, Metz AE, Steele C, Murphy-Ullrich JE, Kabarowski JH. 2013. CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury[S]. *J Lipid Res* 54:1114–1123. doi:10.1194/jlr.m035352

Penberthy KK, Ravichandran KS. 2016. Apoptotic cell recognition receptors and scavenger receptors. *Immunological reviews* 269:44–59. doi:10.1111/imr.12376

Peng Y, Elkon KB. 2011. Autoimmunity in MFG-E8–deficient mice is associated with altered trafficking and enhanced cross-presentation of apoptotic cell antigens. *J Clin Invest* 121:2221–2241. doi:10.1172/jci43254

Perry JSA, Morioka S, Medina CB, Etchegaray JI, Barron B, Raymond MH, Lucas CD, Onengut-Gumuscu S, Delpire E, Ravichandran KS. 2019. Interpreting an apoptotic corpse as anti-inflammatory involves a chloride sensing pathway. *Nat Cell Biol* 21:1532–1543. doi:10.1038/s41556-019-0431-1

Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. *Am J Epidemiol* 27:493–497. doi:10.1093/oxfordjournals.aje.a118408

Ren X, Wen W, Fan X, Hou W, Su Bin, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He Jiangping, Ma W, He Jingjing, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X, Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li Y, Lin J, Ling Y, Liu H, Liu J, Liu N, Liu S-Q, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X,

Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang P, Zhang T, Zhao J, Zhao Peidong, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei J-X, Wei L, Bian X-W, Liu X, Cheng T, Li X, Zhao Pingsen, Wang F-S, Wang H, Su Bing, Zhang Zheng, Qu K, Wang X, Chen J, Jin R, Zhang Zemin. 2021. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* 184:1895-1913.e19. doi:10.1016/j.cell.2021.01.053

Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M, Han Y, Zhang X-Y, Zhou W, Qiu Y, Zhou X. 2020. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. *Cell Mol Immunol* 17:881–883. doi:10.1038/s41423-020-0485-9

Rodrigues TS, Sá KSG de, Ishimoto AY, Becerra A, Oliveira S, Almeida L, Gonçalves AV, Perucello DB, Andrade WA, Castro R, Veras FP, Toller-Kawahisa JE, Nascimento DC, Lima MHF de, Silva CMS, Caetite DB, Martins RB, Castro IA, Pontelli MC, Barros FC de, Amaral NB do, Giannini MC, Bonjorno LP, Lopes MIF, Santana RC, Vilar FC, Auxiliadora-Martins M, Luppino-Assad R, Almeida SCL de, Oliveira FR de, Batah SS, Siyuan L, Benatti MN, Cunha TM, Alves-Filho JC, Cunha FQ, Cunha LD, Frantz FG, Kohlsdorf T, Fabro AT, Arruda E, Oliveira RDR de, Louzada-Junior P, Zamboni DS. 2020. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp Med* 218. doi:10.1084/jem.20201707

Rodriguez-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC, Weiner HL, Green DR, Kuchroo VK. 2010. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. *Proc National Acad Sci* 107:8706–8711. doi:10.1073/pnas.0910359107

Rothlin CV, Hille TD, Ghosh S. 2020. Determining the effector response to cell death. *Nat Rev Immunol* 1–13. doi:10.1038/s41577-020-00456-0

Satyanarayanan SK, Kebir DE, Soboh S, Butenko S, Sekheri M, Saadi J, Peled N, Assi S, Othman A, Schif-Zuck S, Feuermann Y, Barkan D, Sher N, Filep JG, Ariel A. 2019. IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation. *Nat Commun* 10:3471. doi:10.1038/s41467-019-10903-9

Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, Krämer B, Krammer T, Brumhard S, Bonaguro L, Domenico ED, Wendisch D, Grasshoff M, Kapellos TS, Beckstette M, Pecht T, Saglam A, Dietrich O, Mei HE, Schulz AR, Conrad C, Kunkel D, Vafadarnejad E, Xu C-J, Horne A, Herbert M, Drews A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, Müller-Redetzky H, Heim K-M, Machleidt F, Uhrig A, Jarcy LB de, Jürgens L, Stegemann M, Glösenkamp CR, Volk H-D, Goffinet C, Landthaler M, Wyler E, Georg P, Schneider M, Dang-Heine C, Neuwinger N, Kappert K, Tauber R, Corman V, Raabe J, Kaiser KM, Vinh MT, Rieke G, Meisel C, Ulas T, Becker M, Geffers R, Witzenrath M, Drosten C, Suttorp N, Kalle C von, Kurth F, Händler K, Schultze JL, Aschenbrenner AC, Li Y, Nattermann J, Sawitzki B, Saliba A-E, Sander LE, (DeCOI) DC-19 OI, Angelov A, Bals R, Bartholomäus A, Becker A, Bezdan D, Bonifacio E, Bork P, Clavel T, Colome-Tatche M, Diefenbach A, Dilthey A, Fischer N, Förstner K, Frick J-S, Gagneur J, Goesmann A, Hain T, Hummel M, Janssen S, Kalinowski J, Kallies R, Kehr B, Keller A, Kim-Hellmuth S, Klein C, Kohlbacher O, Korbel JO, Kurth I, Landthaler M, Li Y, Ludwig K, Makarewicz O, Marz M, McHardy A, Mertes C, Nöthen M, Nürnberg P, Ohler U, Ossowski S, Overmann J, Peter S, Pfeffer K, Poetsch AR, Pühler A, Rajewsky N, Ralser M, Rieß O, Ripke S, Rocha UN da, Rosenstiel P, Saliba A-E, Sander LE, Sawitzki B, Schiffer P, Schulte E-C, Schultze JL, Sczyrba A, Stegle O, Stoye J, Theis F, Vehreschild J, Vogel J, Kleist M von, Walker A,

Walter J, Wieczorek D, Ziebuhr J. 2020. Severe COVID-19 Is Marked by a Dysregulated
Myeloid Cell Compartment. *Cell* 182:1419-1440.e23. doi:10.1016/j.cell.2020.08.001
Siddiqi HK, Mehra MR. 2020. COVID-19 Illness in Native and Immunosuppressed States: A
Clinical-Therapeutic Staging Proposal. *J Hear Lung Transplant*.
doi:10.1016/j.healun.2020.03.012
Silvin A, Chapuis N, Dunsmore G, Goubet A-G, Dubuisson A, Derosa L, Almire C, Hénon C,
Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E,
Marin N, Szwebel T-A, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S,
Drubay D, Andrieu M, Lhonneur A-S, Saada V, Stoclin A, Willekens C, Pommeret F,
Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, Pène F, Gachot B,
André F, Zitvogel L, Ginhoux F, Fontenay M, Solary E. 2020. Elevated Calprotectin and
Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* 182:1401-
1418.e18. doi:10.1016/j.cell.2020.08.002
Tait JF, Smith C. 1999. Phosphatidylserine Receptors: Role of CD36 in Binding of Anionic
Phospholipid Vesicles to Monocytic Cells*. *J Biol Chem* 274:3048–3054.
doi:10.1074/jbc.274.5.3048
Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. 2011. Shedding of the Mer
Tyrosine Kinase Receptor Is Mediated by ADAM17 Protein through a Pathway Involving
Reactive Oxygen Species, Protein Kinase Cδ, and p38 Mitogen-activated Protein Kinase
(MAPK). *J Biol Chem* 286:33335–33344. doi:10.1074/jbc.m111.263020
Valle DMD, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, Lavin Y,
Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Oekelen OV,
Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-
Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh
S, Merad M, Gnjatic S. 2020. An inflammatory cytokine signature predicts COVID-19
severity and survival. *Nat Med* 26:1636–1643. doi:10.1038/s41591-020-1051-9
Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, Lima M de, Nascimento DC, Schneider
AH, Caetité D, Tavares LA, Paiva IM, Rosales R, Colón D, Martins R, Castro IA, Almeida
GM, Lopes MIF, Benatti MN, Bonjorno LP, Giannini MC, Luppino-Assad R, Almeida SL,
Vilar F, Santana R, Bollela VR, Auxiliadora-Martins M, Borges M, Miranda CH, Pazin-Filho
A, Silva LLP da, Cunha L, Zamboni DS, Dal-Pizzol F, Leiria LO, Siyuan L, Batah S, Fabro
A, Mauad T, Dolhnikoff M, Duarte-Neto A, Saldiva P, Cunha TM, Alves-Filho JC, Arruda E,
Louzada-Junior P, Oliveira RD, Cunha FQ. 2020. SARS-CoV-2–triggered neutrophil
extracellular traps mediate COVID-19 pathology. *J Exp Med* 217. doi:10.1084/jem.20201129
Wang Y, Subramanian M, Yurdagul A, Barbosa-Lorenzi VC, Cai B, Juan-Sanz J de, Ryan TA,
Nomura M, Maxfield FR, Tabas I. 2017. Mitochondrial Fission Promotes the Continued
Clearance of Apoptotic Cells by Macrophages. *Cell* 171:331-345.e22.
doi:10.1016/j.cell.2017.08.041
Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N,
Hummel E, Snow G, Morris D, Stenehjem E, Srivastava R, Brown SM. 2020. Clinical criteria
for COVID-19-associated hyperinflammatory syndrome: a cohort study. *Lancet
Rheumatology*. doi:10.1016/s2665-9913(20)30343-x
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo
X, Yu G. 2021. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.
Innovation 2:100141. doi:10.1016/j.xinn.2021.100141

Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK,
Rymond CC, Gerlach BD, Zheng Z, Kuriakose G, Kevil CG, Koomen JM, Cleveland JL,
Muoio DM, Tabas I. 2020. Macrophage Metabolism of Apoptotic Cell-Derived Arginine
Promotes Continual Efferocytosis and Resolution of Injury. *Cell Metab* 31:518-533.e10.
doi:10.1016/j.cmet.2020.01.001
Zhu N, Wang Wenling, Liu Z, Liang C, Wang Wen, Ye F, Huang B, Zhao L, Wang H, Zhou W,
Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, Wu G, Song J, Tan W. 2020.
Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial
cells. *Nat Commun* 11:3910. doi:10.1038/s41467-020-17796-z
Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, Lee DC, Rodriguez A. 2021.
Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients. *Eur*
Respir J 2100918. doi:10.1183/13993003.00918-2021
Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA,
Zuo M, Yadav V, Wang J, Woodard W, Lezak SP, Lugogo NL, Smith SA, Morrissey JH,
Kanthi Y, Knight JS. 2020. Prothrombotic autoantibodies in serum from patients hospitalized
with COVID-19. *Sci Transl Med* 12:eabd3876. doi:10.1126/scitranslmed.abd3876
976

Figure captions

Figure 1. Macrophages engulf apoptotic cells carrying viable SARS-CoV-2

(A-B) Representative histological findings in post-mortem lung tissue from COVID-19 patients,

obtained by ultrasound-guided minimally invasive autopsy. **(A)** Representative differential

interference contrast (upper panel) and immunofluorescence (middle panel) images of tissue from

P1 patient, immunolabelled with anti-cleaved caspase 3 (red), anti-dsRNA (SARS-CoV2, green),

and stained with DAPI (nuclei, blue) for the detection of caspase-3 activation in infected cells. The

bottom panels show higher magnification of the two selected areas. Arrows indicate cells positive

for both Cl-caspase-3 and dsRNA (purple arrows: ciliated pseudostratified epithelia of a

respiratory bronchiole; white arrows: type II pneumocytes; white arrowheads: type I pneumocytes;

*cleaved-Casp3$^+$ non-epithelial cell). Tissues were scanned by wide-field epifluorescence

imaging. Scale bar: 50 μm. **(B)** Representative immunofluorescence image of tissue from P1

patient immunolabelled for the detection of efferocytosis in situ with anti-CD68 (detecting

macrophages, white), anti-cytokeratin18 (detecting epithelial cells, red), anti-Spike (detecting

SARS-CoV-2, green), and stained with Hoescht (nuclei, blue). Bottom panels show higher

magnification of (a) CD68$^+$ Spike$^+$ macrophage; (b) CD68$^+$ macrophage with cytokeratin18$^+$

content and Spike labeling in the cytosol. Yellow arrows: cytokeratin18$^+$ cells; Yellow arrowheads:

CD68$^+$ cells. Tissues were scanned by wide-field epifluorescence imaging. Scale bar: 50 µm; scale

bar for inset: 10 µm.

(C) PtdSer exposure on the surface of Calu-3 and Vero CCL81 cells in response to UV irradiation

or infection with SARS-CoV-2 (Cov2) for 48h, assessed by annexin V binding (percentage of

annexin V$^+$ cells) and flow cytometric analysis. The gating strategy is shown in Figure S1B.

(D) Flow cytometric analysis of caspase-3 cleavage (Cl-caspase-3) in Calu-3 cells unstimulated

(Cntrl) or infected with SARS-CoV-2 (CoV2) for 48h. The pan-caspase inhibitor z-VAD-FMK

(zVAD; 20 µM) or vehicle (DMSO) were added to cell cultures after viral adsorption.

Representative histogram, geometric mean fluorescence intensity (MFI), and frequency of Cl-

caspase-3$^+$ cells (gated on Total cells/Single cells) are shown. The black line on the histogram

represents the control sample labeled with secondary antibody only.

(E) Quantification by TCID$_{50}$ of SARS-CoV-2 viral loads in Vero CCL81 infected cells. Cells

were collected 48h post-infection, and viral loads were estimated for normalized amounts (10^6

cells) of pre-sorted (Total cells) or Annexin V$^+$ (Ann$^+$ cells) and Annexin V$^-$ (Ann$^-$ cells) cells

isolated by magnetic separation.

(F) Uptake of apoptotic Vero CCL81 cells (labeled with CTFR) in response to UV irradiation

(UV-AC) or infection with SARS-CoV-2 for 48h (Cov2-AC) by human monocyte-derived

macrophages (labeled with CTV). Macrophages were co-incubated with AC for 2h, and

internalization was assessed by flow cytometry. Representative plot and percentage of engulfment

(gated on Total cells/Single cells/Live cells/CTV$^+$ cells; gating strategy in Figure S1D) are shown.

(G) Representative maximal projection of scanning confocal images showing the uptake of UV-

AC or CoV2-AC (from Vero CCL81 cells, CFSE-labelled, green) by human monocyte-derived

macrophages after 2h of co-incubation. Samples were stained with Hoescht (nuclei, blue) and were

immunolabelled with anti-Spike (SARS-CoV-2, red) and anti-CD11b (macrophage, white). Scale

bar: 5 μm.

Boxes represent the mean of three (C, E) or five (D, F) biological replicates, and error bars are ±

S.E.M. Each biological replicate is shown as a circle. Significance was calculated by Student's test

(C) or ANOVA (D, E). *, p<0.05 comparing the indicated groups; ns: non-significant. Data shown

are from one representative out of two experiments performed independently with similar results.

1024

Figure. 2. Engulfment of SARS-CoV-2-infected dying cells impairs macrophage anti-

inflammatory functions.

Macrophages were unstimulated (Cntrl), co-incubated with apoptotic Vero CCL81 cells (AC)

isolated from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, stimulated

with the supernatants of infected apoptotic cells (CoV2-AC Sup), or infected with CoV2 at MOI

of 1 (CoV2), as indicated.

(A) Heatmap showing the expression of M2-marker genes (*CCL18*, *MRC1*, *MMP9*, *PPARγ,* and

CD163) in human monocyte-derived macrophages 24h after stimulation, calculated as log2 fold

change relative to Cntrl. mRNA expression was determined by RT-qPCR and normalized to

GAPDH. Data represent the mean of biological triplicates.

(B) Flow cytometric analysis of CD206 expression on the cell surface of human monocyte-derived macrophages (gated on Total cells/Single cells/Live cells; gating strategy in Figure S2A) 24h after stimulation. Representative histograms and quantification of geometric mean fluorescence intensity (MFI) are shown. The black line on the histogram represents FMO control.

(C-D) Flow cytometric analysis of CD206 expression on the cell surface of THP1-derived macrophages 24h after stimulation. **(C)** Where indicated, isolated CoV2-AC were UV-irradiated for 20 min prior to co-incubation to inactivate SARS-CoV-2. Quantification of CD206 MFI is shown. **(D)** The responses of macrophages to sterile UV-AC and virus-loaded CoV2-AC were compared to infection with CoV2 in the presence of UV-AC (UV-AC + CoV2). Quantification of CD206 MFI is shown.

(E) *IL6* expression in monocyte-derived macrophages 24h after stimulation showed as fold change relative to Cntrl. mRNA expression was determined by RT-qPCR and normalized to GAPDH.

(F) CBA quantification of IL-6 and IL-1β in the culture supernatants of the monocyte-derived macrophages 24h after stimulation.

(G) ELISA quantification of IL-6 in the culture supernatants of THP1-derived macrophages 24h after stimulation. Where indicated, isolated CoV2-AC were UV-irradiated (UV) for 20min or fixed with 2% paraformaldehyde (Fix) for 10 min prior to co-incubation.

(H-J) ELISA quantification of IL-6 in the culture supernatants of human monocyte-derived macrophages 24h after stimulation. **(H)** IL-6 secretion in response to CoV2-AC was compared to apoptotic cells isolated from Vero CCL81 cells similarly infected with Coxsackievirus (Coxsackie-AC). **(I)** PtdSer on the surface of CoV2-AC was blocked by incubation with Annexin V (Ann, 0.1 μg/mL) prior to addition to macrophage cultures (supplemented with Ca^{+2}) to inhibit AC binding.

(J) CoV2-AC and macrophages were co-incubated in the presence of Cytochalasin D (Cyto D, 10

μM) to inhibit AC internalization.

Boxes represent the mean of three biological replicates using cells from a single donor (B, E, F, I,

and J), two donors (H), or THP-1-derived cells (C, G, H). Error bars are ± S.E.M. Each biological

replicate is shown as a circle. Significance was calculated by ANOVA. *, $p<0.05$ comparing the

indicated groups; ns: non-significant. Data shown are from one representative out of at least two

experiments performed independently with similar results.

1064

Figure 3. Engulfment of SARS-CoV-2-infected dying cells suppresses continual efferocytosis

by macrophages

(**A**) Expression of efferocytic receptors in human monocyte-derived macrophages. Macrophages

were unstimulated (Cntrl), co-incubated for 24h with apoptotic Vero CCL81 cells (AC) isolated

from UV-irradiated (UV-AC) or SARS-CoV-2-infected (CoV2-AC) cultures, or infected with

CoV2 at MOI of 1 (CoV2), as indicated. Expression of *CD36*, *SRA-I*, *ITGB5*, *TIMD4*, and *MERTK*

are showed as fold change relative to Cntrl. mRNA levels were determined by RT-qPCR and

normalized to *GAPDH*.

(B-D) Flow cytometric analysis of two-step efferocytosis *in vitro*. **(B)** Schematic representation of

consecutive co-incubations of THP1-derived macrophages with apoptotic cells prior to the

assessment of cell corpse uptake by flow cytometry. **(C)** Percentage of macrophages (CTV-

labelled) with internalized UV-AC or CoV2-AC isolated from Vero CCL81 cell cultures (labeled

with pHRodo), 18h after co-incubation. pHRodo$^+$ macrophages were gated on Total cells/Single

cells/Live cells/CTV$^+$ (gating strategy is displayed in Figure S2L). **(D)** Macrophages were

subsequently incubated with CTFR-labelled, UV-irradiated apoptotic Jurkat cells (UV-Jurkat) for

2h. UV-Jurkat uptake in 2nd round of engulfment is shown as the percentage of CTFR$^+$

macrophages within PhRodo$^+$ populations (gated on Total cells/Single cells/Live cells/ CTV$^+$/

pHRodo$^+$).

Boxes represent the mean of three biological replicates using cells from a single donor in (A) or

THP-1-derived macrophages in quadruplicate (C and D). Error bars are ± S.E.M. Each biological

replicate is shown as a circle. Significance was calculated by ANOVA (A) or Student's test (C and

D). *, p<0.05 comparing the indicated groups; ns: non-significant. Data shown are from one

representative out of two experiments performed independently with similar results.

1088

Figures 4. Lung monocytes and macrophages of severe COVID-19 patients express reduced

levels of efferocytic receptors.

(A-B) Representative histological findings in post-mortem lung tissue from control tissue (Cntrl)

and COVID-19 patients, obtained by ultrasound-guided minimally invasive autopsy. Tissue

samples were immunolabelled with anti-S100A9 (phagocytes, green), **(A)** anti-CD36 (red), or **(B)**

anti-MERTK (red) and stained with DAPI (nuclei, blue). Representative images show cropped

details of lung tissues scanned by wide-field epifluorescence imaging. Scale bar: 10 μm. The mean

fluorescence intensity (MFI) of CD36 and MERTK of at least 200 S1009$^+$ cells are shown (n = 3

individuals per group).

(C) GSEA analysis for efferocytosis-related gene sets in early-infiltrating phagocytes (S1009$^+$

CCL18$^-$) and in anti-inflammatory monocytes-derived macrophages (CD14$^+$ S11009$^-$ CCL18$^+$)

clusters from the bronchoalveolar lavage of mild (M) and severe (S) COVID-19 patients versus

healthy individuals. The corrplot depicts the normalized enrichment score (NES), and p value for

the gene sets indicated on the y axis.

(D) Enriched efferocytosis-related Gene Ontology (GO) terms in genes repressed in virus-positive

alveolar macrophages versus virus-negative cells.

(E) mRNA expression of efferocytic receptors *CD36*, *SRA-I*, *ITGB5*, *TIMD4*, and *MERTK* in

PMBC isolated from the blood of healthy donors (HC, n=25) or patients with COVID-19 (n=42).

mRNA levels were determined by RT-qPCR and normalized to *GAPDH*.

(F) mRNA expression of efferocytic receptors *CD36*, *SRA-I*, *ITGB5*, *TIMD4*, and *MERTK* in

PMBC isolated from the blood of healthy donors (HC, n=13) or patients with acute respiratory

distress syndrome unrelated to COVID-19 (non-COVID-19 ARDS, n=13). mRNA levels were

determined by RT-qPCR and normalized to *GAPDH*.

(G) Stratification of *CD36*, *SRA-1*, and *TIMD4* expression according to COVID-19 patients'

hyperinflammation score (cHIS) (n=42).

(H) Representative maximal projection of scanning confocal images showing the uptake of AC by

monocytes from healthy donors (HC, n=25) and COVID-19 patients (n=16) after 2h of co-

incubation. Actin filaments (F-actin) were stained with phalloidin (AF-488, green), and the nuclei

were stained with Hoescht (blue). White arrows indicate transient reorganization of actin filament

upon engulfment. Scale bar: 5 μm. The uptake of AC by the monocytes was assessed and

associated with the cHIS score of the patients.

Dots represent an S1009[+] cell (A and B) or data from each donor (E-H), the crossing line represents

the mean, and error bars are ± S.E.M. Significance was calculated by Mann-Whitney test (A and

B, E-F) or ANOVA (G and H). *, $p < 0.05$ comparing the indicated groups; ns: non-significant.

1123

1124

1125   **Supporting information captions**

1126

Figure S1. SARS-CoV-2 -apoptotic cells are engulfed by macrophages

(A) Representative histological findings in post-mortem lung tissue from COVID-19 patients, obtained by ultrasound-guided minimally invasive autopsy. Representative differential interference contrast (upper panel) and immunofluorescence (middle panel) images of tissue from P2 patient immunolabelled with anti-cleaved caspase 3 (red), anti-dsRNA (SARS-CoV2, green), and stained with DAPI (nuclei, blue) for the detection of caspase-3 activation in infected cells. The bottom panels show higher magnification of the three selected areas. Arrows indicate cells positive for both Cl-caspase-3 and dsRNA (white arrows: type II pneumocytes; white arrowheads: type I pneumocytes; *cleaved-Casp3$^+$ non-epithelial cell). Tissues were scanned by wide-field epifluorescence imaging. Scale bar: 100 μm (upper and middle panels) or 50 μm (selected areas).

(B) Representative gating strategy used to determine the PtdSer exposure on the surface of Calu-3 and Vero CCL81 cells in response to UV irradiation or infection with SARS-CoV-2 (Cov2) for 48h, assessed by annexin V binding and flow cytometric analysis (related to Figure 1C)

(C) TCID$_{50}$ quantification of SARS-CoV-2 viral loads from detached, apoptotic Calu-3 and Vero CCL81 cells (CoV2-AC, 10^6 cells) and their cell-free supernatants, collected 48h post-infection and isolated as described in the Methods.

(D) Uptake of apoptotic Calu-3 and Vero CCL81 cells (labeled with CFSE) in response to UV irradiation (UV-AC) or infection with SARS-CoV-2 for 48h (Cov2-AC) by THP-1-derived macrophages (labeled with CTFR). Macrophages were co-incubated with AC for 2h, and internalization was assessed by flow cytometry. Representative gating strategy, plots, and percentage of engulfment (gated on Total cells/Single cells/Live cells/CTFR$^+$ cells) are shown.

(E) Human monocyte-derived macrophages or THP-1-derived macrophages were unstimulated

(Cntrl), co-incubated with apoptotic Vero CCL81 cells isolated from UV-irradiated (UV-AC) or

SARS-CoV-2-infected (CoV2-AC) cultures, stimulated with the supernatants of infected apoptotic

cells (CoV2-AC Sup), or infected with SARS-CoV-2 at MOI of 1 (CoV2), as indicated. The

percentage of cellular viability was measured using a viability probe 24h post-stimulation and

analysis by flow cytometry (gated on Total cells/Single cells).

Boxes represent the mean of three biological replicates, and error bars are ± S.E.M. Each biological

replicate is shown as a circle. Significance was calculated by Student's test (C-D) or ANOVA (E).

*, $p < 0.05$ comparing the indicated groups; ns: non-significant. Data shown are from one

representative out of two experiments performed independently with similar results.

1158

Figure S2. Engulfment of SARS-CoV-2-infected dying cells switches macrophage phenotype

in response to efferocytosis.

(A) Representative gating strategy used to determine the CD206 expression on the surface of

macrophages in response to the different stimulus by flow cytometry (backgating corresponds to

FMO control showed in Fig. 2B)

(B) THP-1-derived macrophages were unstimulated (Cntrl), co-incubated with UV-AC, CoV2-

AC, or CoV2-AC Sup obtained from Vero CCL81 cells, or infected with CoV2, as indicated.

Expression of *MRC1* in macrophages showed as fold change relative to Cntrl was assessed 24h

after stimulation. mRNA expression was determined by RT-qPCR and normalized to *GAPDH*.

(C-D) THP-1-derived macrophages were incubated with UV-AC, Cov2-C, or CoV2-Sup obtained

from Calu-3 **(C)** or Vero CCL81 **(D)** infected cell cultures. CD206 expression on the cell surface

24h after stimulation was assessed by flow cytometry (gated on Total cells/Single cells/Live cells).

Representative histograms and quantification of geometric mean fluorescence intensity (MFI) of

CD206 are shown.

(E) Quantification by $TCID_{50}$ of the SARS-CoV-2 viral loads in 10^6 AC isolated from Vero CCL81

infected cells, either intact (CoV2-AC) or UV-irradiated for 20 min for viral inactivation (CoV2-

AC UV).

(F) THP-1-derived macrophages were incubated with UV-AC, Cov2-AC, or CoV2-Sup obtained

from infected Vero CCL81 cells or infected with Cov2. Expression of *MRC1* in macrophages

showed as fold change relative to Cntrl was assessed 24h after stimulation. mRNA expression was

determined by RT-qPCR and normalized to *GAPDH*.

(G-H) THP-1-derived macrophages were incubated for 24h with UV-AC, Cov2-C, or CoV2-Sup

obtained from Calu-3 or Vero CCL81 infected cell cultures, as indicated. IL-6 **(G)** and IL-1β **(H)**

in the culture supernatants were quantified by CBA.

(I) Quantification by $TCID_{50}$ of the viral loads in 10^6 AC isolated from Vero CCL81 cells similarly

infected with either Coxsackie virus (Coxsackie-AC) or SARS-CoV-2 (CoV2-AC).

(J) ELISA quantification of IL-6 in the culture supernatants of THP-1-derived macrophages

stimulated with Cov2-AC for 24h. PtdSer on the cell surface was blocked to inhibit AC binding

by incubation of CoV2-AC with Annexin V (Ann, 0.01 and 0.1 µg/mL) prior to addition to

macrophage cultures.

(K) THP-1-derived macrophages were incubated with UV-AC or Cov2-AC obtained from infected

Vero CCL81 cells or infected with CoV2. Expression of the efferocytic receptors *CD36*, *SRA-I*,

ITGB5, *TIMD4*, and *MERTK* showed as fold change relative to Cntrl was assessed 24h after

stimulation. mRNA levels were determined by RT-qPCR and normalized to *GAPDH*.

(L) Representative gating strategy used to determine CTV-labelled macrophage populations for

the two-step efferocytosis experiment showed in Figures 3C and D.

(M) THP-1-derived macrophages (CTV-labelled) were infected or not with SARS-CoV-2 (CoV2)

at MOI of 1 for 18h and subsequently were incubated with CTFR-labelled, UV-irradiated apoptotic

Jurkat cells (UV-Jurkat) for 2h. UV-Jurkat uptake is shown as the percentage of CTFR$^+$ (gated on

Total cells/Single cells/Live cells/ CTV$^+$).

Boxes represent the mean of three biological replicates, and error bars are ± S.E.M. Each biological

replicate is shown as a circle. Significance was calculated by ANOVA (B-D, F-H, and J-K) or

Student's test (I and M). *, $p < 0.05$ comparing the indicated groups; ns: non-significant. Data

shown are from one representative out of two experiments performed independently with similar

results.

1204

Figure S3. Analysis of cytokine production and monocyte subpopulations in COVID-19

patients.

(A) CBA quantification of IL-6, IL-8, IL-10, IL-1β, TNF-α, and IL-12 in the plasma from healthy

donors (HC, n=19) and COVID-19 patients (n=28).

(B) Representative gating strategy used to determine the percentage of classical, intermediate, non-

classical monocyte subpopulations, CD36, and HLA-DR expression on the surface of blood

monocytes from HC and COVID-19 patients (related to Figs. S3 C-I). Displayed plots correspond

to CD36-PE FMO control.

(C-D) The frequency **(C)** and absolute number **(D)** of CD14$^+$ blood monocytes from HC (n=22)

and COVID-19 patients (n=26) were determined by flow cytometry (gated on Total cells/Single

cells/Live cells/Lin$^-$).

(E) Percentage of HLA-DR$^+$ monocytes in blood from healthy donors (HC, n=22) and COVID-19

patients (n=26), determined by flow cytometry (gated on Total cells/Single cells/Live cells/Lin$^-$

/CD14$^+$).

(F-H) Frequency of **(F)** classical CD14$^+$CD16$^-$, **(G)** intermediate CD14^{hi}CD16$^+$ and **(H)** non-

classical CD14^{int}CD16$^+$ monocytes in blood samples from healthy donors (HC, n=22) and

COVID-19 patients (n=26) are shown (gated on Total cells/Single cells/Live cells/Lin$^-$ CD14$^+$).

(I) Representative plots, frequency, and MFI of CD36 expression in CD14^{hi} monocytes from HC

and COVID-19 patients (gated on Total cells/Single cells/Live cells/Lin$^-$ CD14^{hi}).

(J) The uptake of zymosan particles (labeled with Texas-Red) by monocytes from healthy donors

(HC, n=7) and COVID-19 patients (n=7) was determined by epifluorescence microscopy. Each

dot represents the data from each donor, the crossing line represents mean, and error bars $\pm$ S.E.M.

Significance was calculated by the Mann-Whitney test (A and C-I) or Student's test (J). *, $p<0.05$

comparing the indicated groups; ns: non-significant.

1229

1230 **Table S1.** Custom gene sets incorporating associated to efferocytic pathway and related to human

1231 diseases (related to Figure 4C).

1232

1233 **Table S2.** Medical characteristics of COVID-19 patients.

1234

1235 **Table S3.** Medical characteristics of nonCOVID-19 ARDS patients.

1236

Table S1. Custom gene sets incorporating genes associated to efferocytic pathways and related to human diseases (Penberthy and Ravichandran, 2016; Boada-Romero et al., 2020) (related to Figure 4C).

Term	Gene				
Recognition (eat-me receptors)	GAS6	SCARB1	MARCO	MEGF10	STAB1
	MERTK	ITGB3	MFGE8	MSR1	STAB2
	ADGRB1	ITGAV	AXL	TIMD4	AGER
	LRP1	CD36	TYRO3	C1QA	SCARF1
Engulfment and processing	RAC2	RHOBTB1	DNM1L	ABCA1	ATG7
	RAC1	RHOG	ELMO1	RUBCN	ATG16L1
	RHOH	RAB14	SLC2A1	BECN1	GULP
	TREX1	TYROBP	SLC12A4	PIK3C3	
	RHOBTB2	DOCK1	DNASE2	ATG5	

Table S2. Medical characteristics of COVID-19 patients

Demographics		%
Number	60	
Age	61.48 ± 16.07	
Female		43.3
Comorbidities		
Hypertension	35	58
Obesity	32	57
Diabetes	22	37
History of smoking	8	15
Heart disease	16	27
Lung disease	11	18
Kidney disease	8	14
Cancer	6	10
History of stroke	1	2
Immunodeficiency	1	2
Autoimmune diseases	2	3
Laboratorial findings		
CRP (mg/dL)	11.78 ± 8.09	
D-Dimers (µg/mL)	3.30 ± 3.15	
LDH (U/L)	855.39 ± 533.04	
Ferritin (ng/mL) of smoking	1494.31 ± 1374.06	
Haemoglobin (g/dL)	12.25 ± 3.35	
Neutrophils (cell/mm3)	8004.18 ± 5026.49	
Lymphocytes (cell/mm3)	1572.42 ± 1098.80	
Platelets (count/mm3)	251066.67 ± 105331.26	
Medications		
Heparin	58	97
Antibiotics	56	93
Glucocorticoids	57	95
Oseltamivir	14	25
Antimalarial	2	4
Respiratory status		
Mechanical ventilation	42	70
Nasal-cannula oxygen	60	100
pO2	79.87 ± 35.53	
SatO2	91.84 ± 9.90	
Disease severity		
Mild	0	0
Moderate	10	17.24
Severe	50	86.21
Outcome		
Death	27	46.55

*CRP: C-reactive protein (normal value <0.5 mg/dl); **D-dimers (normal value <0.5 µg/ml); :

#LDH: lactate dehydrogenase (normal range: 120–246 U/liter); &Ferritin (normal range: 10-291 ng/ml)

Table S3. Medical characteristics of nonCOVID-19 ARDS patients

Demographics		%
Number	10	
Age	67.10 ± 12.04	
Female		40
Comorbidities		
Hypertension	8	80
Obesity	4	40
Diabetes	6	60
History of smoking	7	70
Heart disease	6	60
Lung disease	5	50
Kidney disease	2	20
Cancer	2	20
History of stroke	1	10
Immunodeficiency	1	10
Autoimmune diseases	0	0
Laboratorial findings		
CRP (mg/dL)*	8.82 ± 10.29	
D-Dimers (µg/mL)**	4.69 ± 3.69	
LDH (U/L)#	1700.22 ± 2542.49	
Ferritin (ng/mL)&	N.D.	
Haemoglobin (g/dL)	15.00 ± 4.74	
Neutrophils (cell/mm3)	9300.00 ± 4998.67	
Lymphocytes (cell/mm3	2070.00 ± 1418.18	
Platelets (count/mm3)	222300.000 ± 116946.38	
Medications		
Heparin	9	90
Antibiotics	9	90
Glucocorticoids	6	60
Oseltamivir	1	10
Antimalarial	0	0
Respiratory status		
Mechanical ventilation	7	70
Nasal-cannula oxygen	10	100
pO2	71.27 ± 18.18	
SatO2	91.55 ± 7.73	
Disease severity		
Mild	0	0
Moderate	1	10
Severe	9	90
Outcome		
Death	7	70

*CRP: C-reactive protein (normal value <0.5 mg/dl); **D-dimers (normal value <0.5 µg/ml); :

#LDH: lactate dehydrogenase (normal range: 120–246 U/liter); &Ferritin (normal range: 10-291 ng/ml)